This inventor holds 3 USPTO granted patents, plus 1 CIPO patent. Top assignee: Biorex Kutato-Fejleszto Kft. Active years: 1992-1994.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1992-1994
Title: Gyorgy Blasko: Innovator in Diabetes Treatment
Introduction
Gyorgy Blasko is a notable inventor based in Budapest, Hungary. He has made significant contributions to the field of medical chemistry, particularly in the development of compounds aimed at treating diabetes-related complications. With a total of 3 patents to his name, Blasko's work is recognized for its potential impact on healthcare.
Latest Patents
Blasko's latest patents include innovative compounds such as 0-(3-amino-2-hydroxypropyl)-hydroximic acid halides and hydroximic acid derivatives. These compounds are specifically designed to be useful in treating diabetes angiopathy, a serious complication of diabetes that affects blood vessels. His research focuses on the synthesis and application of these hydroximic acid derivatives, showcasing his commitment to advancing medical treatments.
Career Highlights
Throughout his career, Gyorgy Blasko has been associated with Biorex Kutato-Fejleszto Kft., where he has contributed to various research projects. His expertise in medicinal chemistry has positioned him as a key figure in the development of therapeutic solutions for diabetes. His innovative approach and dedication to research have earned him recognition in the scientific community.
Collaborations
Blasko has collaborated with esteemed colleagues such as Peter L Nagy and Bela Balazs. These partnerships have fostered a collaborative environment that enhances the research and development of new medical compounds.
Conclusion
Gyorgy Blasko's contributions to the field of diabetes treatment through his innovative patents and collaborative efforts highlight his importance as an inventor. His work continues to pave the way for advancements in medical chemistry, ultimately benefiting patients suffering from diabetes-related complications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile